SOURCE: CNS Response, Inc.

CNS Response, Inc.

September 29, 2009 12:26 ET

CNS Response Announces New Payer Programs

COSTA MESA, CA--(Marketwire - September 29, 2009) - CNS Response, Inc. (OTCBB: CNSO) today announced new pilot programs with CalOptima and Comprehensive Behavioral Health Management Inc., both located in Orange County, California, for use of its referenced-EEG® (rEEG®) testing service.

rEEG guides physicians in medication selection for patients with treatment-resistant mental disorders. Economic research has shown that these patients, who have failed two or more prior treatments, have over four times higher direct medical costs and seven times higher drug costs than other patients. Driving payer interest are clinical results indicating that using rEEG guidance for medication selection could provide better clinical and financial outcomes.

The CalOptima contract, effective September 21, 2009, covers a Quality Pilot Program to evaluate the Company's rEEG testing service, supporting evidence-based treatment for CalOptima's OneCare Medicare Advantage members. CalOptima is one of five County Organized Healthcare Systems (COHS) in the United States, which are public/private agencies authorized under federal law to administer Medicaid and Medicare benefits within a defined geographic setting. CalOptima is known for its innovative programs to provide access and quality healthcare services.

The Company also announced agreements with Comprehensive Behavioral Health Management Inc. (CBHM), covering two separate pilot programs for national insurers within its Southern California network. CBHM manages a network of over 3,000 behavioral providers in California and Arizona, and provides utilization review, quality improvement and claims payment services for some of the nation's largest health plans. The objective of both rEEG pilot programs is to demonstrate cost effectiveness, quality and scalability of the testing service across a typical plan population.

CNS Response CEO George Carpenter noted, "We have known CalOptima and CBHM for a long time and they are industry trend-setters. We are proud to be working with organizations committed to quality improvement and that embrace evidence-based medicine in an area with such an unmet need."

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the matters to be considered at the Company's 2009 Annual Meeting of Stockholders and/or the purported special meeting called by Mr. Brandt or his purported solicitation of written consents. The Company intends to file a proxy statement with the Securities and Exchange Commission ("SEC"). CNS SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. CNS Security holders will be able to receive the proxy statement and other relevant documents free of charge at the SEC's Web site at www.sec.gov or from the Company at 2755 Bristol Street, Suite 285, Costa Mesa, CA 92626.

Participants in Solicitation

CNS and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the matters to be considered at the Company's 2009 Annual Meeting of Stockholders and/or any purported special meeting called by Mr. Brandt or his purported solicitation of written consents. Information regarding the interests of the Company's directors and executive officers in the proxy contest will be included in its definitive proxy statement.

About CNS Response

Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient's brain waves and compare the results to an extensive patient outcomes database. The process produces a rEEG® report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient's own brain physiology. To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

About CalOptima

CalOptima, an integrated health care system, administers health insurance programs for children, low income families, and persons with disabilities in Orange County. The company offers CalOptima Kids, a plan for healthy families and healthy kids; OneCare, a Medicare advantage special needs plan, which provides access to a network of primary care doctors and specialists, as well as hospitals; and offers health education in various languages. It also provides programs for members with specific needs, including expectant mothers and new parents, teens, diabetics, seniors, and members with disabilities. CalOptima was founded in 1995 and is based in Orange, California. Visit the CalOptima website at www.CalOptima.org.

About Comprehensive Behavioral Management

Comprehensive Behavioral Health Management ("CBHM") specializes in meeting the ongoing needs of our customers and the growing challenges in the behavioral health market by providing specialized behavioral health solutions. Serving more than 1.2 million members from Commercial, Senior and Medicaid populations, CBHM strives to not only improve the health and well-being of their members but also provide a viable behavioral health solution with measurable cost savings for their customers. Visit the CalOptima website at www.comprehensivebehavioral.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact Information

  • Investor and Media Relations:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    949.553.9748
    Email Contact